Literature DB >> 9452933

A histochemical demonstration of altered cytochrome oxidase activity in the rat brain by neuroleptics.

J A Prince1, M S Yassin, L Oreland.   

Abstract

Regional alterations in neuronal functional activity were examined in the rat brain using cytochrome-c oxidase (COX) histochemistry following chronic neuroleptic treatment. Haloperidol, fluphenazine, and clozapine were administered to animals for 28 days after which profiles of COX activity were generated. Significant increases in COX activity were evident in area 2 of the frontal cortex of all treated animals. Clozapine and fluphenazine, but not haloperidol, caused significant increases in COX activity in the caudate nucleus, nucleus accumbens, septum, and pontine nucleus. Statistically significant increases in COX activity were also observed in hippocampal CA2 and CA3 subfields in clozapine treated animals. Results offer support for the concept that neuroleptics achieve their therapeutic effects primarily via an enhancement of brain function in the frontal cortex, but also point to other brain regions which may be involved in the actions of these drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9452933     DOI: 10.1016/s0924-977x(97)00036-9

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  7 in total

1.  Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain.

Authors:  Emilio L Streck; Gislaine T Rezin; Luciana M Barbosa; Lara C Assis; Eliane Grandi; João Quevedo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-03       Impact factor: 3.000

Review 2.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

3.  Abnormal high-energy phosphate molecule metabolism during regional brain activation in patients with bipolar disorder.

Authors:  C Yuksel; F Du; C Ravichandran; J R Goldbach; T Thida; P Lin; B Dora; J Gelda; L O'Connor; S Sehovic; S Gruber; D Ongur; B M Cohen
Journal:  Mol Psychiatry       Date:  2015-03-10       Impact factor: 15.992

4.  The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

5.  Systematic analysis of genome-wide fitness data in yeast reveals novel gene function and drug action.

Authors:  Maureen E Hillenmeyer; Elke Ericson; Ronald W Davis; Corey Nislow; Daphne Koller; Guri Giaever
Journal:  Genome Biol       Date:  2010-03-12       Impact factor: 13.583

6.  Mitochondrial complex I and III gene mRNA levels in schizophrenia, and their relationship with clinical features.

Authors:  Süleyman Akarsu; Deniz Torun; Abdullah Bolu; Murat Erdem; Salih Kozan; Mehmet Ak; Hatice Akar; Özcan Uzun
Journal:  J Mol Psychiatry       Date:  2014-12-10

7.  Schizophrenia and Leigh syndrome, a simple comorbidity or the same etiopathogeny: about a case.

Authors:  Leila Mnif; Rim Sellami; Jawaher Masmoudi
Journal:  Pan Afr Med J       Date:  2015-12-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.